Millions of German patients now face higher health insurance fundpremiums in addition to the controversial higher charges for drug prescriptions and medical treatment planned by the government.
A number of leading health funds, including the major supplementary funds, have already sent proposals to their management boards to raise contribution rates. Their aim is to undermine the new mechanism planned by the government to establish a clear link between increases in premiums and patient charges.
Under the government arrangement, there will be an across-the-board increase of about 5% from July 1. If a health fund planned to increase its premium rates after March 11, the patient charges would rise by one Deutschemark for every 0.1% rise in premiums. A number of funds say they have proposed rises in premiums before March 11, including most of the white-collar funds.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze